The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer

Katherine E. Francis, S.I. Kim, Michael Friedländer, Val Gebski, I. Ray-Coquard, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, Tamar Perri, Tomasz Huzarski, Cristina Martín-Lorente, Sabrina Chiara Cecere, Nicoletta Colombo, Beyhan Ataseven, Keiichi Fujiwara, Gabe S. Sonke, Ignace Vergote, Éric Pujade-Lauraine, Ji‐Hoon Kim, Chee Khoon Lee